二甲双胍联合格列齐特或维格列汀降糖效果比较

目的 观察单用二甲双胍血糖未达标的2型糖尿病患者,在二甲双胍基础上分别加用格列齐特或者维格列汀治疗,对比其疗效及安全性差异.方法 54例单用二甲双胍而血糖未达标的2型糖尿病患者,随机分组加用格列齐特或维格列汀治疗16周,检测治疗前后体重、空腹血糖、早餐后2h血糖、糖化血红蛋白及低血糖发生情况.结果 16周后,2组患者空腹血糖、餐后2h血糖,糖化血红蛋白治疗前后差异显著（P＜0.05）;2组间比较差异无统计学意义（P＞0.05）;格列齐特组体重增加（1.61±1.2） kg,维格列汀组体重增加（0.84±1.19） kg,2组对比差异有统计学意义（P＜0.05）;格列齐特组患者低血糖报告共9人次,维格列汀组无低血糖报告.结论 对于单用二甲双胍治疗未能达标患者,第2种口服降糖药使用格列齐特或者维格列汀均可有效降低血糖,两者疗效相当,使用维格列汀者有着低血糖发生率低、体重无明显增加的特点.

Comparison Study on Curative Effect of Metformin combined with Gliclazide or Vildagliptin in Type 2 Diabetes Patients

Objective To observe the type 2 diabetes patients whose blood glucose did not reach the standard when taking Metformin alone. These patients have received Gliclazide or Vildagliptin treatment. The curative effects and safety differences were compared. Methods 54 type 2 diabetes patients whose blood glucose did not reach the standard when taking Metformin alone were randomly grouped, taking Gli- clazide or Vildagliptin respectively for 16 weeks. Occurrence of body weight, fasting and postprandial blood glucose, HbAlc and hypoglycemia were tested before and after the treatment. Results After 16 weeks, there were significant differences before and after treatment in body weight, fasting and postpran- dial blood glucose and HbAlc （P 〈 0.05） ; Comparison differences between two groups have no statisti- cal significance; an average body weight gain of 1.61 ＋ 1.2kg was observed in the gliclazide group in contrast with 0.84 - 1.19 body weight gain noted in Vildagliptin group. Comparison between two groups have statistical significance （ P 〈 0.05 ） ; 9 hypoglycemia events were reported in the Gliclazide group while none in the Vildagliptin group. Conclusion Regarding type 2 diabetes patients whose blood glucose did not reach the standard when taking Metformin alone, the second type of oral hypoglycemic drugs with Gliclazide or Vildaglipin can both effectively reduce blood glucose with comparable Curative effect. Low incidence of blood glucose and nc significant weight gain can be observed in patients taking Vildaglipin.